Zenas Biopharma Inc

ZBIO remains in a Stage 2 uptrend with a rising 200-day SMA and active Lockout Rally dynamics driven by short-covering demand. The medium-term bias is bullish, and the recent pullback into the confluence of the 9EMA, 20EMA, and 50SMA near the support zone around $31–$31.50 was met with buying interest, indicating acceptance. Under the Lockout Rally override, short-term timing is bullish, and a Buy Now at this support confluence is recommended. A decisive break below the 50SMA and EMAs would invalidate this bullish posture.

• ↑FDA accepted obexelimab BLA for IgG4-RD; PDUFA target May 27, 2027
• ↑$673.9M cash and equivalents fund operations through Q2 2029
• ↓Q2 2026 net loss widened to $111.5M from $52.2M a year ago